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Abstract
We developed a new magnetic nanoparticles sandwich-like immunoassay using protein cage 
nanoparticles (PCN) for signal amplification together with graphite furnace atomic absorption 
spectrometry (GFAAS) for quantification of organophosphorylated acetylcholinesterase adduct 
(OP-AChE), the biomarker of exposure to organophosphate pesticides (OPs) and nerve agents. 
OP-AChE adducts were firstly captured by titanium dioxide coated magnetic nanoparticles (TiO2-
MNPs) from the sample matrixes through metal chelation with phospho-moieties, and then 
selectively recognized by anti-AChE antibody labeled on PCN which was packed with lead 
phosphate in its cavity (PCN-anti-AChE). The sandwich-like immunoreaction was performed 
among TiO2-MNPs, OP-AChE and PCN-anti-AChE to form TiO2-MNPs/OP-AChE/PCN-anti-
AChE immunocomplex. The complex could be easily isolated from the sample solution with the 
help of magnet, and the released lead ions from PCN were detected by GFAAS for the 
quantification of OP-AChE. Greatly enhanced sensitivity was achieved because PCN increased the 
amount of metal ions in the cavity of each apoferritin. The proposed immunoassay yielded a linear 
response over a broad OP-AChE concentrations from 0.01 nM to 2 nM, with a detection limit of 2 
pM, which has enough sensitivity for monitoring of low-dose exposure to OPs. This new method 
showed an acceptable stability and reproducibility and was validated with OP-AChE spiked 
human plasma.
Keywords
Protein cage; amplification; phosphorylated acetylcholinesterase; magnetic nanoparticles; 
immunoassay; graphite furnace atomic absorption spectrometry
* Corresponding author. liangpei@mail.ccnu.edu.cn; annie.du@wsu.edu. 
HHS Public Access
Author manuscript
Analyst. Author manuscript; available in PMC 2016 June 22.
Published in final edited form as:














Many organophosphates (OPs) have been extensively used in agriculture as insecticides or 
acaricides. 1 As a result, OPs contaminations have been widespread in air, water, soil and 
food, and there is a potential for human exposure. Exposure to even small amounts of OPs 
can be fatal because they exert their toxicity through irreversible phosphorylation and 
inactivation of acetylcholinesterase (AChE) in the central nervous system, often leading to 
perturbation of the nerve conduction system and to the rapid paralysis of vital functions of 
living systems. 2, 3 Thus, developing a simple, rapid, sensitive and reliable method for 
monitoring of OPs exposure and screening poison victims is desired.
OPs exposure will produce numbers of relevant biomarkers in biological system, including 
phosphorylated enzyme adducts, hydrolysis products and unbound free OPs. 4, 5 Detection 
of metabolites and free OPs could be performed by gas chromatography-mass spectrometry 
(GC-MS) or liquid chromatography-mass spectrometry (LC-MS), but these methods are not 
accurate due to the high affinity of OPs to cholinesterase (ChE) and other proteins. 6, 7 
Phosphorylated ChE adduct (OP-ChE) is a more effective and sensitive biomarker for 
directly evaluation of OPs exposure in the absence of baseline. 8 Clinical measurement of 
OP-ChE adducts biomarker shows great promise for early predictions. Although GC-MS 
and LC-MS are powerful tools for the detection of OP-ChE adducts, they have some 
inherent disadvantages such as complicated and expensive analysis, and lack of portability 
and real-time results. 9
Immunoassay of OP-ChE adducts is an optional technology with high sensitivity and 
selectivity. Combined with nanomaterial labels based signal amplification strategies, 
immunoassy have attracted considerable interest and are extensively applied in the 
determination of proteins because of their low-background signal, high signal to noise ratio, 
low cost, long lifetime, inherent miniaturization and multiplexing capability. 10, 11 The 
nanomaterials used in immunoassay include metal nanoparticles (gold, silver), 12, 13 
semiconductor nanoparticles (quantum dots) 14, 15 and markers loaded nanocarriers (carbon 
nanotubes, apoferritin, silica nanoparticles, and liposome beads. 16 Antibodies (antigens) 
labeled with nanomaterials could retain their bioactivity and interact with their counterparts. 
Quantification is generally achieved by measuring the specific signal of a nanomaterial label 
after immunoreaction. Issues to be considered with nanomaterial labels include the difficulty 
of making uniformly sized metal nanoparticles and the unstable nature of the linkage 
between the nanoparticles and the proteins. 17 Apoferritin-templated nanoparticles overcome 
all of these limitations. Apoferritin, a typical protein cage, is an iron storage protein with a 
diameter of 12.5 nm. 18 It has a cavity of 8 nm in diameter, surrounded by 24 polypeptide 
subunits, which can store up to 4500 iron atoms in its fully saturated form; however, it more 
commonly holds 2000 iron atoms per apoferritin in the iron phosphate form. There are 6 
hydrophobic channels and 8 hydrophilic channels connecting the outside of apoferritin with 
its interior. 8 hydrophilic channels facilitate the passage of metal ions and small molecules 
into the cavity of the protein. 19, 20 Due to the center cavity structure as well as the 
dissociation and reconstructive characteristics of apoferritin at different pH environments, it 
provides a restrained environment to produce encoded nanoparticle tags with uniformly size, 
and the labels are compatible with biomolecules due to the protein cage. 21, 22 We have 
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taken the advantages of apoferritin to synthesize inorganic nanoparticles as labels for the 
electrochemical immunoassay of DNA and protein, and confirmed the stability and the 
specific binding with antigen of the apoferritin-labeled antibody. Highly sensitivity could be 
easily obtained due to the large quantities of detectable metal ions in the cavity of each 
apoferritin. 23-25 Nevertheless, there was no report on apoferritin-labeled immunoassay 
followed by atomic spectrometry detection until now.
Immunoassay detection of OP-ChE is a highly sensitive method with high selectivity, but 
sometimes challenged with unavailability of OP-specific antibodies. To help address this 
issue, zirconia or titania noparticles (ZrO2 or TiO2 NPs) were performed as the selective 
sorbents to recognize the phosphorylation moiety based on the strong chelation with 
phospho-moieties. 26, 27 Magnetic titania nanoparticles was synthesized (composite of 
Fe3O4, SiO2, and TiO2) with an aim to combine the magnetic property of magnetite particles 
and affinity of TiO2 toward phosphopeptides for fast enrichment of phosphopeptides. 28 
TiO2 or ZrO2 NPs could be used as a special “similar antibodies” because of its specific 
capture phosphate group in OP-ChE and good biocompatibility. 29, 30
In this paper, we demonstrated a novel magnetic nanoparticles based immunoassay for 
highly selective and sensitive detection of OP-ChE adducts in human plasma using 
apoferritin encoded metallic tags in the signal amplification strategy. Phosphorylated 
acetylcholinesterase (OP-AChE) was prepared by incubating AChE with paraoxon, which 
was used as the model target in this study. OP-AChE adducts were captured by titanium 
dioxide coated magnetic nanoparticles (TiO2-MNPs) from the sample matrixes through 
metal chelation with phospho-moieties, and then selectively recognized by anti-AChE 
antibody labeled on protein cage nanoparticles (PCN) which was packed with lead 
phosphate (PCN-anti-AChE) to form a sandwich-like immunocomplex. The complex could 
be easily isolated from the sample solution with the help of magnet, and dissolved in HNO3 
solution to release the lead ion which were detected by graphite furnace atomic absorption 
spectrometry (GFAAS) for the quantification of OP-AChE. The use of TiO2-MNPs not only 
surpasses the drawback of the scarce commercial availability of OP-specific antibody, but 
also favors the separation of the immunocomplex from the sample matrices.
 Experimental
 Apparatus
A TAS-990 atomic absorption spectrophotometer (Beijing Purkinge Genereal Instrument 
Co. Ltd., Beijing, China) with a deuterium back-ground correction and a GF990 graphite 
furnace atomizer system was used for the determination of Pb. A lead hollow-cathode lamp 
was used as radiation source at 283.3 nm. The optimum operating parameters for GFAAS 
are given in Table 1. All measurements were carried out in the integrated absorbance (peak 
area) mode. Attenuated total reflection Fourier-transform infrared spectra (ATR-FTIR) were 
recorded on a Nexus 470 FTIR (Nicolet, USA) equipped with an omni sampler over 32 
scans, which was used to characterize the formation of OP-AChE adduct.
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 Reagents and materials
Anti-AChE antibody was purchased from Abcam Inc. (Cambridge, MA). Apoferritin, 
human AChE, paraoxon, avidin, biotin N-hydroxysuccinimide (biotin-NHS), bovine serum 
albumin (BSA), phosphate buffer saline (PBS), Tris-HCl buffer were purchased from Sigma-
Aldrich Co. (St. Louis, MO). SuperBlock T20 (TBS) blocking buffer and Bicinchoninic acid 
assay (BCA) kit were purchased from Thermo scientific (Rockford, IL). Tween-20, lead 
nitrate (AR) were purchased from Shanghai Chemistry Reagent Company (Shanghai, 
China). TiO2-MNPs were synthesized by hydrolysis of tetrabutyltitanate on the surface of 
Fe3O4 magnetic nanospheres, and characterized by ATR-FTIR, transmission electron 
microscope and X-ray diffraction as previously described elsewhere. 31 All stock and buffer 
solutions were prepared with double distilled water.
 Preparation of OP-AChE adduct
OP-AChE was by mixing 50 μL AChE (500 nmol L−1) and 100 μL paraoxon (750 μmol L−1) 
in double distilled water and incubated at room temperature for 12 h. The enzyme activity 
was determined with Ellman assay 32 until AChE was completely inhibited by paraoxon. 
The resulting solution was then exhaustively dialyzed with 0.01 mol L−1 Tris-HCl buffer 
solution (pH 8.0) for 72 h to remove unbound paraoxon and the outcome p-nitrophenoxy. 
Moreover, the resultant OP-AChE was concentrated with ultrafiltration to a final volume of 
1.0 mL and stored at −20 °C for the future using. The protein concentrations of the OP-
AChE stock solution were determined to be 6.8 μmol L−1 by BCA method. 33 The working 
solutions of OP-AChE were obtained by appropriate dilution of the stock solution with Tris-
HCl buffer in the following experiment.
 Preparation of lead phosphate packed PCN
Lead phosphate packed PCN was prepared according to our previous method. 21 Briefly, 40 
μL apoferritin (50 mg mL−1) was diluted with Tris-HCl (0.1 mol L−1, pH 8.0) to a volume of 
1.5 mL in EP tube. Approximately 250 μL of 6 mmol L−1 lead nitrate was slowly introduced 
into the above apoferritin solution, and the mixture was continuously stirred for 1 h to allow 
the lead ions to diffuse into the cavity of apoferritin. Then 250 μL PBS (0.2 mol L−1, pH 7.0) 
was drop-by-drop added into the solution and the mixture was stirred for 1 h to form the 
metal phosphate core inside apoferritin. Excess lead ions remaining outside the apoferritin 
were precipitated with PBS buffer. The mixture was centrifuged at 5000 rpm for 5 min. The 
supernatant was washed three times with 0.1 mol L−1 Tris-HCl using an ultrafiltration (10 
KD), and reconstituted to a final volume of 1.0 mL. The concentrations of apoferritin and Pb 
ion were determined by the BCA method and GFAAS, respectively. The numbers of Pb ion 
loaded in apoferritin, calculated by comparing the concentrations of apoferritin and Pb ion in 
the nanoparticle solution, are estimated to be 1400 per apoferritin.
 Preparation of PCN-anti-AChE conjugate
The PCN-anti-AChE was prepared using an avidin as a bridge to link biotin modified anti-
AChE and apoferritin. 34 In this procedure, biotin labeled PCN (biotin-PCN) and biotin 
labeled anti-AChE (biotin-anti-AChE) were first prepared, respectively. And then native 
unlabeled avidin was used to connect both of them since avidin possesses 4 active sites 
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which will react with one biotin residue and operate as acceptor for another biotin-labeled 
protein. Briefly, 800 μL of the above prepared PCN nanoparticles were mixed with 200 μL 
0.1 mg mL−1 biotin-NHS and stirred for 3 h at room temperature. The mixture was dialyzed 
against Tris-HCl overnight to remove excess biotin-NHS. The resulting biotin-PCN was 
reconstituted into a 1.0 mL solution containing 0.5% BSA and stored at 4 °C. The same 
process was performed to prepare the biotin-anti-AChE. Subsequently, 1.0 mL 0.06 mg 
mL−1 avidin was mixed with the above biotin-PCN and reacted for 2 h to form avidin-biotin-
PCN conjugate. Then an amount of biotin-anti-AChE was added at an equal molar 
equivalent to the avidin-biotin-LPA solution, and the reaction proceeded for 2 h to form 
PCN-biontin-avidin-biotin-anti-AChE (PCN-anti-AChE) conjugate. Excess agents were 
removed using an ultrafiltration (10 KD). The resulting PCN-anti-AChE was dispersed in 
Tris-HCl buffer containing 1% BSA and kept at 4 °C for the further using.
 Immunoassay procedure
A sandwich-like immunoassay shown in figure 1 was used for the determination of OP-
AChE. A certain amount of TiO2-MNPs were dispersed by ultrasound in acetate buffer (pH 
4.0) to a concentration of 0.5% (w/v), and 25 μL aliquot of TiO2-MNPs was transferred into 
1.5 mL EP tube. Then, 25 μL aliquot of OP-AChE or spiked samples, which was diluted to 
the desired concentration with acetate buffer containing 0.5% BSA, was introduced into the 
EP tube and vortexed for 30 min at room temperature. The mixtures were washed intensively 
with Tris-HCl buffer and blocked with TBS blocking buffer for 30 min in order to reduce 
nonspecific binding. After magnetically separated and re-dispersed in acetate buffer, 10 μL 
of PCN-anti-AChE conjugate was added, and the incubation of 40 min with gentle shaking 
results in a sandwich immunocomplex (TiO2-MNPs/OP-AChE/PCN-anti-AChE). After 
rinsing with Tris-HCl buffer thoroughly and magnetic separation, the complex attached on 
the tube wall. 20 μL of 1.0 mol L−1 HNO3 solution was added into the tube and mixed with 
the complex for 5 min to release Pb from PCN, and then diluted to 100 μL with double 
distilled water. 10 μL of the solution was injected into GFAAS for the determination of Pb.
 Result and Discussion
 Characterization of OP-AChE by ATR-FTIR
In this study, OP-AChE adduct was prepared by incubating AChE with paraoxon, and used 
as a model of OP-ChE. FTIR spectra of OP-AChE were recorded to confirm the formation 
of phosphorylated AChE adduct. As shown in figure 2. Strong bands resulting from O–C–C 
stretching (1043 and 931cm−1) are exhibited in the spectra of OP-AChE, while some bands 
associated with conjugated double bonds (1611, 1595, 1525 and 1490 cm−1) and aryl-NO2 
(1349, 1286 and 861cm−1) in the spectra of paraoxon was absent. These results consistent 
with the understanding that the phosphorylation of AChE by paraoxon is synchronous with 
the release of p-nitrophenoxy (–OPhNO2) to yield a stable, covalent diethylphosphoserine 
ester bond.
 Evaluation of immunoaffinities between TiO2-MNPs, antibody and OP-AChE
The immunoaffinities of TiO2-MNPs, OP-AChE and PCN-anti-AChE antibody were studied 
by GFAAS measurements. Here, 1.0 nM nonphosphorylated AChE, 1.0 nM paraoxon and 
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1% BSA were served as the control samples to be simultaneously examined as the 
challenging proteins, and the results were shown in figure 3. It can be seen that the 
absorbance signal for OP-AChE is much higher than that for nonphophorylated AChE, 
paraoxon and BSA, indicating the effective immunoreactions between TiO2-MNPs, OP-
AChE and PCN-anti-AChE to form the sandwich-like immunocomplex. The absorbance 
signals from these control samples might be ascribed to the nonspecific adsorption of PCN-
anti-AChE to the TiO2-MNPs.
 Optimization of detection conditions for OP-AChE
In this work, TiO2-MNPs is used as “similar antibodies” for the trapping of OP-AChE, its 
amount influenced the amount of captured OP-AChE which accounted for the amount of 
PCN-anti-AChE. The effect of the amount of TiO2-MNPs on the Immunoassay was studied 
through varying the concentration of TiO2-MNPs dispersion from 0.1% to 1% (w/v), and the 
results were shown in figure 4. As can be seen, the absorbance signal of Pb increased 
quickly with the increasing of TiO2-MNPs concentration from 0.1% to 0.5%, and increased 
slightly after 0.5%. In the other hand, excessive TiO2-MNPs may cause the nonspecific 
adsorption and influence on the Immunoassay response. So 0.5% TiO2-MNPs dispersion 
was used in the experiments.
Acidity is another important issue for the capturing of OP-AChE by TiO2-MNPs. As 
reported in literature, TiO2 is an amphoteric oxide that can react either as Lewis acid or base 
depending on the pH of the solution. 35 Under acidic conditions, TiO2 with positively 
charged titanium atoms (Lewis acid) shows high binding affinity to phosphate ion (Lewis 
base), suggesting that high binding selectivity to phosphorylated protein could be achieved. 
In this work, it was found that the highest absorbance signal of Pb was achieved at pH 4.0. 
Lower acidity does not mean the best condition since phosphate ions may be prone to bind 
with hydrogen ions, and the protein may be damaged. Therefore, pH 4.0 was selected for the 
capturing of OP-AChE.
The incubation time is one of the important parameters for both TiO2-MNPs capturing of 
OP-AChE and PCN-anti-AChE recognition of the captured OP-AChE. As shown in figure 5, 
the absorbance signal of Pb increased with the increasing incubation time and tend to a 
steady value after 30 min (TiO2-MNPs capturing) and 40 min (PCN-anti-AChE recognition), 
respectively, which were selected for TiO2-MNPs capturing and PCN-anti-AChE 
recognition of OP-AChE in the sandwich immunoassay. Longer incubation time could result 
in a large non-specific signal.
Nonspecific adsorption has a significant influence on the immunoassay response. As can be 
seen in figure 6, obviously negligible signal was observed when using 0 nM OP-AChE and 
5.0 nM nonphosphorylated AChE as the control sample without blocking. To minimize 
nonspecific adsorption, TBS buffer was used as the blocking agent and 1% BSA was added 
to the synthesized PCN-anti-AChE conjugate. Although both the absorbance signals of the 
OP-AChE sample and the control sample decreased after blocking due to the shield effect of 
the blocking agent, the single-to-noise was improved greatly.
Liang et al. Page 6













For GFAAS determination of Pb after the immunoreaction, a pyrolysis step prior to the 
atomization is needed to remove the matrix as much as possible which could considerably 
reduce the magnitude of the background signal. In order to avoid Pb losing during the 
pyrolysis step and obtain the high absorbance signal, the optimal pyrolysis and atomization 
temperatures should be selected. Pyrolysis and atomization curves were established using 
the solution obtained after the immunoassay procedure, and shown in figure 7. From the 
curves, 500 °C and 1700 °C were selected as the optimal pyrolysis and atomization 
temperatures, respectively.
 Analytical performance of the immunoassay
Under optimal experimental conditions, the proposed immunoassay was examined with 
different concentrations of OP-AChE. A well-defined absorbance signal from lead ion was 
observed and increased with the increase of OP-AChE concentration. The resulting 
calibration plot of absorbance signal vs. concentration was linear over 0.01-2 nM OP-AChE 
with a correlation of 0.9995. The limit of detection (LOD), based on a signal-to-noise ratio 
(S/N) of 3, was 2 pM. Since the average AChE concentrations in human plasma and 
erythrocyte are around 0.12 nM and 3 nM respectively, the proposed immunoassay has 
enough sensitivity for monitoring of low-dose exposure to OPs. Such a detection limit is 
comparable to that of mass spectrometry analysis of organophosphorylated cholinesterase 
adducts (1.0~4.0 ng mL−1), 8 and 10 times lower than our previous result of 0.02 nM 
adducts using the electrochemical detection. 24 The precision of the proposed method was 
evaluated by analyzing one sample for six replicate determinations, and the coefficients of 
variation (CV) was 4.6% at 0.1 nM OP-AChE level.
A series of OP-AChE human plasma samples were used to investigate the accuracy and 
practical viability of the proposed immunoassay. The OP-AChE human plasma samples 
were prepared by spiking different amounts of OP-AChE with known concentration to 
human plasma. Each sample was determined three times, and the results were summarized 
in Table 2. The recoveries were in the range of 94-105%, indicating that the magnetic 
nanoparticles based immunoassay was reliable.
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Schematic illustration of the sandwich-like immunoassay of OP-AChE adducts
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FTIR spectrum of OP-AChE adduct
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GFAAS responses of the immunoassay for OP-AChE, nonphophorylated AChE, paraoxon 
and BSA
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Effect of the amount of TiO2-MNPs on the immunoassay responses
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Effect of the incubation time on the immunoassay responses
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Effect of the non-specific adsorption on the immunoassay responses
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Pyrolysis curve and atomization curve for Pb
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Table 1
Operating parameters for GFAAS
Parameters
Lamp current (mA) 2.0
Wavelength (nm) 283.3
Slit (nm) 0.4
Ar flow rate (mL min−1) 300 (stopped during atomizing)
Sample volume (μL) 10
Temperature program
Drying 110 °C (Ramp 18s, Hold 10s)
Pyrolysis 500 °C (Ramp 10s, Hold 10s)
Atomization 1700 °C (Ramp 0s, Hold 4s)
Cleaning 2000 °C (Ramp 1s, Hold 3s)
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Table 2
Analytical results for the spiked human plasma samples with immunoassay (n=3)
Sample No. 1 2 3 4 5 6
Add (nM) 0 0.02 0.05 0.10 0.50 1.00
Found (nM) nd 0.021 0.047 0.976 0.518 1.018
Recovery (%) -- 105 94 97.6 103.6 101.8
nd: no detected
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